REFERENCES
  1. Ishida J, Saitoh M, Ebner N, Springer J, D. Anker, Von Haehling. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications 2020; 3: 25–37. DOI: 10.1002/rco2.9.
  2. Bowers C, Chang J, Momany F, Folkers K. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro.Mol Endocrinol 1977;287–292.
  3. Bowers C, Momany F, Reynolds G: In vitro and in vivo activity of a small synthetic pep- tide with potent GH releasing activity. In64th Annual Meeting of the Endocrine Soci- ety, San Francisco : 1982:205.
  4. Bowers C. GH releasing peptides-structure and kinetics. J Paediatric Endocrinol Metabol 1993;6:21–32.
  5. Howard AD, Feighner SD, Cully DF, Arena JP. A receptor in pituitary and hypothala- mus that functions in growth hormone re- lease.Science 1996;273:974.
  6. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated pep- tide from stomach.Nature 1999;402: 656–660.
  7. Prakash A, Goa KL. Sermorelin. BioDrugs
  8. 1999;12:139–157.
  9. Barron JL, Coy DH, Millar RP. Growth hor- mone responses to growth hormone- releasing hormine (1–29)-NH 2 and a D-Ala2 analog in normal men. Peptides 1985;6: 575–577.
  10. Carpino PA. Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Expert Opin Ther Pat 2002; 12:1599–1618.
  11. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, et al. Effects of GHRP-2 and hexarelin, two synthetic GH- releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Pep- tides1997;18:885–891.
  12. Imbimbo B, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, et al. Growth hormone-releasing activity of hexarelin in humans. Eur J Clin Pharmacol 1994;46: 421–425.
  13. Rahim A, O’Neill PA, Shalet SM. Growth hor- mone status during long-term hexarelin therapy. J Clin Endocrinol Metabol 1998; 83:1644–1649.
  14. Broglio F, Benso A, Gottero C, Muccioli G, Deghenghi R, Ghigo E, et al. Endocrine activities of alexamorelin (Ala-His-D-2- methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. Eur J Endocrinol 2000;143:419–425.
  15. Suckling K. Discontinued drugs in 2005: car- diovascular drugs.Expert Opin Investig Drugs 2006;15:1299–1308.
  16. Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, et al. Pharmaco- logical characterisation of a new oral GH se- cretagogue, NN703. Eur J Endocrinol 1999; 141:180–189.
  17. Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Horm IGF Res 2000;10:193–198.
  18. Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Horm IGF Res 2001;11: 41–48.
  19. Svensson J, Monson J, Vetter T, Hansen TK, Savine R, Kann P, et al. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hor- mone deficiency. Clin Endocrinol (Oxf)2003;58:572–580.
  20. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, et al. General pharmacology of KP-102 (GHRP-2), a po- tent growth hormone-releasing peptide. Arzneimittelforschung2004;54:868–880.
  21. Editorial A. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP- 102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R & D 2004;5:236–239.
  22. Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen L, Sarosiek I, et al. Safety and efficacy of ghrelin agonist TZP-101 in re- lieving symptoms in patients with diabetic gastroparesis: a randomized, placebo- controlled study. Neurogastroenterol Motil2010;22:1069.
  23. Losa M, Schopohl J, Müller O, Von Werder K. Stimulation of growth hormone secre- tion with human growth hormone releas- ing factors (GRF 1–44, GRF 1–40, GRF 1– 29) in normal subjects. J Mol Med1984;62:1140–1143.
  24. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs: Clinic Immunothera- peutics, Biopharmaceut Gene Therapy 1999;12:139–157.
  25. Neyzi O, Yordam N, Oca G, Bundak R, Darendeliler F, Agikǧoz E, et al. Growth re- sponse to growth hormone releasing hor- mone (1–29)-NH2 compared with growth hormone. Acta Paediatr 1993;82:16–21.
  26. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcuta- neous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metabol 1996; 81:1189–1196.
  27. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hor- mone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging 2006;27:318–323.
  28. Mericq Vn, Cassorla F, Salazar T, Avila A, Iñiguez Gn, Bowers CY, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metabol 1998;83:2355–2360.
  29. Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, et al. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimula- tion test for the diagnosis of adult GH defi- ciency. J Clin Endocrinol Metabol 2013;98: 2422–2429.
  30. Beck DE, Sweeney WB, McCarter MD, Group IS. Prospective, randomized, con- trolled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the manage- ment of postoperative ileus in bowel resec- tion patients. Int J Colorectal Dis 2014;29: 1527–1534.
  31. Mosińska P, Zatorski H, Storr M, Fichna J. Future treatment of constipation- associated disorders: role of relamorelin and other ghrelin receptor agonists. J Neurogastroenterol Motility2017;23:171.
  32. Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, et al. Safety and efficacy of ulimorelin administered postop- eratively to accelerate recovery of gastroin- testinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials. Diseases of the Colon & Rectum 2013;56:888–897.
  33. Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ. The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial. Diseases of the Colon & Rectum 2010;53:126–134.
  34. Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, et al. Relamorelin re- duces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis.Gastroenterology 2016;151:87, e86–96.
  35. Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, et al. Relamorelin re- lieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2015, 13;2312, e2311–2319.
  36. Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D. Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, con- trolled trial. Dig Dis Sci 2016;61:852–860.
  37. Ejskjaer N, Wo J, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.Neurogastroenterol Motil 2013;25:e140–e150.
  38. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr2011;53:183–189.
  39. Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy J-P, Cote P, Abribat T. A placebo-controlled, dose- ranging study of a growth hormone releas- ing factor in HIV-infected patients with ab- dominal fat accumulation. AIDS 2005;19: 1279–1287.
  40. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in pa- tients with HIV. N Engl J Med 2007;357: 2359–2370.
  41. Falutz J, Allas S, Mamputu J-C, Assaad H, Zoltowska M, Michaud SE, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22:1719–1728.
  42. Falutz J, Potvin D, Mamputu J-C, Assaad H, Zoltowska M, Michaud S-E, et al. Ef- fects of tesamorelin, a growth hormone- releasing factor, in HIV-infected patients with abdominal fat accumulation: a ran- domized placebo-controlled trial with a safety extension. JAIDS2010;53:311–322.
  43. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. Effects of an oral growth hormone secretagogue in older adults.J Clin Endocrinol Metabol 2009;94:1198–1206.
  44. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 2017;28:1949–1956.
  45. Carty M, Bowie AG. SARM: From immune regulator to cell executioner. Biochem Pharmacol. 2019 Mar;161:52-62. doi: 10.1016/j.bcp.2019.01.005. Epub 2019 Jan 8.
  46. Fujii S, Kagechika H. Androgen receptor modulators: a review of recent patents and reports (2012-2018). Expert Opin Ther Pat. 2019 Jun;29(6):439-453. doi: 10.1080/13543776.2019.1618831. Epub 2019 May 19.
  47. Fragkaki AG, Sakellariou P, Kiousi P, Kioukia-Fougia N, Tsivou M, Petrou M, Angelis Y. Human in vivo metabolism study of LGD-4033. Drug Test Anal. 2018 Nov;10(11-12):1635-1645. doi: 10.1002/dta.2512. Epub 2018 Nov 8.
  48. Clark RV, Walker AC, Andrews S, Turnbull P, Wald JA, Magee MH. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women. Br J Clin Pharmacol. 2017 Oct;83(10):2179-2194. doi: 10.1111/bcp.13316. Epub 2017 Jun 10.
  49. Neil D, Clark RV, Magee M, Billiard J, Chan A, Xue Z, Russell A. GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass in Healthy Older Men and Women. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3215-3224. doi: 10.1210/jc.2017-02644.
  50. Carty M, Kearney J, Shanahan KA, Hams E, Sugisawa R, Connolly D, Doran CG, Muñoz-Wolf N, Gürtler C, Fitzgerald KA, Lavelle EC, Fallon PG, Bowie AG. Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM. Immunity. 2019 Jun 18;50(6):1412-1424.e6. doi: 10.1016/j.immuni.2019.04.005. Epub 2019 May 7.
  51. Piper T, Dib J, Putz M, Fusshöller G, Pop V, Lagojda A, Kuehne D, Geyer H, Schänzer W, Thevis M4. Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. Drug Test Anal. 2018 Nov;10(11-12):1646-1656. doi: 10.1002/dta.2527. Epub 2018 Nov 18.
  52. Ahram M, Mustafa E, Abu Hammad S, Alhudhud M, Bawadi R, Tahtamouni L, Khatib F, Zihlif M. The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells. Endocr Res. 2018 Aug;43(3):203-214. doi: 10.1080/07435800.2018.1455105. Epub 2018 Mar 26.
  53. Miller CP, Shomali M, Lyttle CR, O’Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508. eCollection 2011 Feb 10.
  54. Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0.
  55. Krishnan V, Patel NJ, Mackrell JG, Sweetana SA, Bullock H, Ma YL, Waterhouse TH, Yaden BC, Henck J, Zeng QQ, Gavardinas K, Jadhav P, Saeed A, Garcia-Losada P, Robins DA, Benson CT. Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology. 2018 May;6(3):455-464. doi: 10.1111/andr.12479. Epub 2018 Mar 12.
  56. Coss CC, Jones A, Dalton JT. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs. 2016 Aug;34(4):458-67. doi: 10.1007/s10637-016-0353-8. Epub 2016 Apr 22.
  57. Welch RD, Guo C, Sengupta M, Carpenter KJ, Stephens NA, Arnett SA, Meyers MJ, Sparks LM, Smith SR, Zhang J, Burris TP, Flaveny CA. Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome. Mol Metab. 2017 May 19;6(7):703-714. doi: 10.1016/j.molmet.2017.05.001. eCollection 2017 Jul.
  58. Gu L, Shi Y, Xu W, Ji Y. PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206. Oncol Res. 2019 Aug 8;27(8):923-933. doi: 10.3727/096504019X15518706875814. Epub 2019 Apr 8.